Foundation Medicine and PMV Pharma Partner To Develop Companion Diagnostic

Foundation Medication, Inc., a trailblazer in molecular profiling for cancer, and Pharmaceuticals, Inc. reported an alliance to foster EFoundation Medication's tissue-based extensive genomic profiling test, FoundationOne CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational treatment for patients with privately progressed or metastatic solid tumours that have a TP53 Y220C change.

“The innovative science driven by PMV Pharma’s efforts specific to TP53 Y220C has the potential to offer a new therapeutic option for patients in this area of high unmet medical need,” said Troy Schurr, chief biopharma business officer at Foundation Medicine. “We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”

Rezatapopt (PC14586) is an investigational, first-in-class, particular p53 reactivator intended to balance out p53 Y220C proteins. The TP53 Y220C transformation makes a little pocket in the p53 protein, making it thermally temperamental and unfit to connect with DNA. Rezatapopt is an orally accessible small molecule intended to specifically tie to a pocket in the p53 Y220C protein, prompting the reclamation of the wild-type p53 tumor suppressor function. The US Food and Drug Administration (FDA) granted Fast Track designation to rezatapopt for the treatment of patients with privately progressed or metastatic solid tumours with a TP53 Y220C transformation, and is the subject of the continuous registrational, tumor-agnostic PYNNACLE phase 2 clinical trial.